The estimated Net Worth of David Soergel is at least $587 Thousand dollars as of 10 December 2015. David Soergel owns over 27,217 units of Trevena Inc stock worth over $13,108 and over the last 11 years David sold TRVN stock worth over $574,279.
David has made over 3 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently David sold 27,217 units of TRVN stock worth $287,139 on 10 December 2015.
The largest trade David's ever made was selling 27,217 units of Trevena Inc stock on 10 December 2015 worth over $287,139. On average, David trades about 6,961 units every 46 days since 2014. As of 10 December 2015 David still owns at least 1,750 units of Trevena Inc stock.
You can see the complete history of David Soergel stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA, PA, 19406.
Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, and Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Trevena Inc executives and other stock owners filed with the SEC include: